Top

International Journal of Colorectal Disease

Published in:

01-07-2009 | Original Article

Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy

Authors: V. Moreno García, P. Cejas, M. Blanco Codesido, J. Feliu Batlle, J. de Castro Carpeño, C. Belda-Iniesta, J. Barriuso, J. J. Sánchez, J. Larrauri, M. González-Barón, E. Casado

Published in: International Journal of Colorectal Disease | Issue 7/2009

Abstract

Background

The purpose of this study was to identify clinical and pathological parameters to improve prediction of disease-free survival (DFS) and overall survival (OS) in patients treated with neoadjuvant chemoradiotherapy for rectal cancer.

Methods

Between July 1995 and May 2007, 148 patients with primary rectal adenocarcinoma received neoadjuvant chemoradiotherapy followed by mesorectal excision. Preoperative treatment included various protocols, UFT and leucovorin (28%) and oxaliplatin-based chemotherapy (72%). Clinical and pathological variables were evaluated in relation to patient outcomes.

Results

Thirteen percent of patients achieved a complete pathologic response. No response or minimal response as defined by Dworak (Tumor Regression Grade 0/1) was observed in 30 patients (20%). At a median follow-up of 37 months, the 3-year DFS and OS were 64% and 83%, respectively. Pre-treatment serum carcinoembryonic antigen (CEA) level ≤ 2.5 ng/ml was associated with higher DFS (74 vs. 53%; p = 0.018), higher complete pathologic responses (21 vs. 9%; p = 0.05), and less recurrences (24 vs. 44%; p = 0.014).

Conclusion

The data suggest that a CEA level ≤ 2.5 ng/ml might be a predictor not only of tumor response, as has been suggested before, but also of DFS. This finding could be useful in the future to predict individual risk and to develop more aggressive or alternative strategies.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef

Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results—EORTC 22921. J Clin Oncol 23:5620–5627PubMedCrossRef

Bujko K, Kepka L, Michalski W, Nowacki MP (2006) Does rectal cancer shrinkage induced by preoperative radio(chemo) therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 80:4–12PubMedCrossRef

Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRef

Losi L, Luppi G, Gavioli M, Iachetta F, Bertolini F, D’Amico R, Jovic G, Bertoni F, Falchi AM, Conte PF (2006) Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis 21:645–651PubMedCrossRef

Machiels JP, Aydin S, Bonny MA, Hammouch F, Sempoux C (2006) What is the best way to predict disease-free survival after preoperative radiochemotherapy for rectal cancer patients: tumor regression grading, nodal status, or circumferential resection margin invasion? J Clin Oncol 24:1319–1PubMedCrossRef

Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH (2007) Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109:1750–1755PubMedCrossRef

Yoon SM, Kim DY, Kim TH, Jung KH, Chang HJ, Koom WS, Lim SB, Choi HS, Jeong SY, Park JG (2007) Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 69:1167–1172PubMed

Greene FL, Compton CC, Fritz AG, Shah JP, Winchester DP (2006) AJCC Cancer Staging Atlas. Springer, New York (GENERIC) Ref Type: GenericCrossRef

10.

Feliu J, Calvilio J, Escribano A, de Castro J, Sanchez ME, Mata A, Espinosa E, Garcia GA, Mateo A, Gonzalez BM (2002) Neoadjuvant therapy of rectal carcinoma with UFT–leucovorin plus radiotherapy. Ann Oncol 13:730–736PubMedCrossRef

11.

Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19–23PubMedCrossRef

12.

Moertel CG, O’Fallon JR, Go VL, O’Connell MJ, Thynne GS (1986) The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 58:603–610PubMedCrossRef

13.

Harrison LE, Guillem JG, Paty P, Cohen AM (1997) Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg 185:55–59PubMed

14.

Carriquiry LA, Pineyro A (1999) Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 42:921–929PubMedCrossRef

15.

Wolmark N, Fisher B, Wieand HS, Henry RS, Lerner H, Legault-Poisson S, Deckers PJ, Dimitrov N, Gordon PH, Jochimsen P (1984) The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199:375–382PubMedCrossRef

16.

Sener SF, Imperato JP, Chmiel J, Fremgen A, Sylvester J (1989) The use of cancer registry data to study preoperative carcinoembryonic antigen level as an indicator of survival in colorectal cancer. CA Cancer J Clin 39:50–57PubMedCrossRef

17.

Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, Oettgen HF (1978) Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299:448–451PubMed

18.

Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW (2006) Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol 13:645–650PubMedCrossRef

19.

Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M, Willett C (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979–994PubMed

20.

Ptok H, Meyer F, Steinert R, Vieth M, Ridwelski K, Lippert H, Gastinger I (2007) No prognostic impact of isolated lymphovascular invasion after radical resection of rectal cancer—results of a multicenter observational study. Int J Colorectal Dis 22:749–756PubMedCrossRef

21.

Garcia-Aguilar J, Pollack J, Lee SH, de Hernandez AE, Mellgren A, Wong WD, Finne CO, Rothenberger DA, Madoff RD (2002) Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. Dis Colon Rectum 45:10–15PubMedCrossRef

22.

Manger T, Stroh C (2004) Accuracy of endorectal ultrasonography in the preoperative staging of rectal cancer. Tech Coloproctol 8(Suppl 1):s14–s15PubMedCrossRef

23.

Beets-Tan RG, Beets GL (2004) Rectal cancer: review with emphasis on MR imaging. Radiology 232:335–346PubMedCrossRef

24.

Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, Ried T (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826–1838PubMedCrossRef

25.

Giralt J, Eraso A, Armengol M, Rossello J, Majo J, Ares C, Espin E, Benavente S, de Torres I (2002) Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54:1460–1465PubMed

26.

Kim JS, Kim JM, Li S, Yoon WH, Song KS, Kim KH, Yeo SG, Nam JS, Cho MJ (2006) Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 66:195–200PubMed

27.

Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ (2006) Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 32:55–64PubMedCrossRef

Title: Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy
Authors: V. Moreno García
P. Cejas
M. Blanco Codesido
J. Feliu Batlle
J. de Castro Carpeño
C. Belda-Iniesta
J. Barriuso
J. J. Sánchez
J. Larrauri
M. González-Barón
E. Casado
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 7/2009
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-009-0682-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2009

Plasminogen fragment K1–3 inhibits expression of adhesion molecules and experimental HCC recurrence in the liver

In-house colorectal laparoscopic preceptorship: a model for changing a unit’s practice safely and efficiently

Systemic cytokine response after emergency and elective surgery for colorectal carcinoma

A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer

Syndrome of inappropriate antidiuresis (SIAD) in a patient with rectal carcinoma undergoing preoperative radiation

Liver metastases after colonic carcinoma—palliative chemotherapy plus curcumin